Adjunctive ziprasidone in major depression and the current status of adjunctive atypical antipsychotics

American Journal of Psychiatry

Volumn 172, Issue 12, 2015, Pages 1176-1178

  Nelson, J Craig ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BREXPIPRAZOLE; BUSPIRONE; ESCITALOPRAM; FLUOXETINE; LITHIUM SALT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ZIPRASIDONE; ANTIDEPRESSANT AGENT; CITALOPRAM; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADJUVANT THERAPY; AKATHISIA; ANXIETY DISORDER; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON DEPRESSION RATING SCALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; PAIN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; THERAPY RESISTANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PIPERAZINES; THIAZOLES;

EID: 84949267271     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15091220     Document Type: Review

References (21)

1. Papakostas GI, Fava M, Baer L, et al: Ziprasidone augmentation of escitalopram for major depressive disorder: Efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2015; 172:1251-1257
2. Citrome L: Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: An analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010; 122:39-48
3. Papakostas GI, Petersen TJ, Nierenberg AA, et al: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRIresistantmajordepressivedisorder. JClinPsychiatry2004;65:217-221
4. DunnerDL,AmsterdamJD, SheltonRC, et al:Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study. J Clin Psychiatry 2007; 68:1071-1077
5. Lenze EJ, Mulsant BH, Blumberger DM, et al: Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: A randomized placebocontrolled trial. Lancet (Epub ahead of print, Sep 24, 2014)
6. Nelson JC, Papakostas GI: Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980-991
7. Iovieno N, Papakostas GI: Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? J Clin Psychiatry 2012; 73:676-683
8. KamijimaK, HiguchiT, Ishigooka J, et al: Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 2013; 151:899-905
9. Fava M, Mischoulon D, Iosifescu D, et al: A double-blind, placebocontrolled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81:87-97
10. FDAapprovesnewdrug to treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder (news release). Washington, DC, US Food and Drug Administration, July 13, 2015. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm454647.htm
11. Nelson JC, Baumann P, Delucchi K, et al: A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168:269-275
12. Citrome L: Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antipsychotic: What is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Int J Clin Pract 2015; 69:978-997
13. TrivediMH,FavaM,Wisniewski SR, et al: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252
14. Bauer M, Dell'osso L, Kasper S, et al: Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatmentresistant major depressive disorder. J Affect Disord 2013; 151: 209-219
15. Andersen SW, Clemow DB, Corya SA: Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005; 66: 1468-1476
16. Michelson D, AmsterdamJD, Quitkin FM, et al: Changes inweight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156: 1170-1176
17. WeberE, Stack J, Pollock BG, et al: Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: A double-blind randomized trial. Am J Geriatr Psychiatry 2000; 8:245-250
18. Rapaport MH, Gharabawi GM, Canuso CM, et al: Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31:2505-2513
19. Corya SA, Andersen SW, Detke HC, et al: Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study. J Clin Psychiatry 2003; 64:1349-1356
20. Berman RM, Thase ME, Trivedi MH, et al: Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 2011; 7:303-312
21. Brunner E, Tohen M, Osuntokun O, et al: Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 2014; 39: 2549-2559